Centre Cuts Cancer Drug Rates; Supreme Court Asks Why Cap Isn't Expanded
The central government has revised maximum retail prices for 543 anti-cancer drug brands following a 30 per cent trade margin cap imposed by the National Pharmaceutical Pricing Authority, with generic and biosimilar medicines seeing cuts of up to 93 per cent taking effect from November 9. The Supreme Court has reserved its order while questioning the disparity between retailer costs and retail prices, asking why trade margin caps cannot be extended to other essential medicines. Meanwhile, the Karnataka government has mandated hospitals to disclose both purchase costs and maximum retail prices on patient bills from November 1 to improve billing transparency.




